Overview
Good Clinical Practice (GCP) training has always been a cornerstone of clinical trial conduct, but the adoption of ICH E6(R3) in January 2025 has introduced new requirements and expectations for training and retraining of clinical trial staff. The revised guideline, which came into effect on July 23, 2025, and was implemented by Health Canada on April 1, 2026, represents a significant modernization of GCP principles, emphasizing flexibility, proportionality, and quality-by-design to better support diverse clinical trial models and evolving technologies . This guide explains what ICH E6(R3) requires for GCP training and why it is mandatory for clinical trial staff.
https://www.gxptrainings.com/course-category/gcp-training
Why GCP Training Is Mandatory Under ICH E6(R3)
GCP training is mandatory because it ensures that all personnel involved in clinical trials understand their responsibilities and can conduct trials in accordance with ethical and scientific standards. ICH E6(R3) reinforces this requirement while introducing a more nuanced, risk-based approach to determining training needs .
Regulatory Requirement – ICH E6(R3) requires that investigators be qualified by education, training, and experience to assume responsibility for the proper conduct of the trial. They must provide evidence of such qualifications and be familiar with the appropriate use of the investigational product .
Role-Based Training – The guideline emphasizes that trial-related training for persons assisting in the trial should correspond to what is necessary to enable them to fulfill their delegated trial activities that go beyond their usual training and experience .
Sponsor Responsibility – Sponsors must utilize appropriately qualified individuals and service providers throughout the trial process. When using service providers, the sponsor is responsible for assessing the suitability of the service provider and ensuring that staff training is sufficient .
Training Requirements for Investigators
Under ICH E6(R3), investigators have specific training obligations. The investigator should be qualified by education, training, and experience to assume responsibility for the proper conduct of the trial .
Qualification Evidence – The investigator must provide evidence of his/her qualifications and be familiar with the proper use of the investigational product as described in the information sources provided by the sponsor .
Delegation and Oversight – If the investigator delegates trial-related tasks to others, he/she must ensure that these individuals have sufficient knowledge of the trial protocol, investigational product, and their assigned trial tasks .
Retraining Considerations – Retraining should be considered whenever there are significant updates to trial guidelines, such as the publication of the new E6 R3 version. The need for retraining depends on the role and tasks of the individual .
Training Requirements for Sponsors
Sponsors also have significant training responsibilities under ICH E6(R3). The sponsor must utilize appropriately qualified individuals and service providers throughout the trial .
Service Provider Oversight – When the sponsor uses service providers, it is their responsibility to assess the suitability of the service provider. The sponsor must ensure that the selected service provider can properly perform the tasks assigned to them .
Shared Responsibility – Since the sponsor is responsible for selecting the investigator/organization, the sponsor has a shared responsibility to ensure that each investigator is qualified based on training, orientation, and experience .
Key Changes in ICH E6(R3) Training Requirements
ICH E6(R3) introduces several key changes that affect GCP training requirements. Understanding these changes is essential for compliance .
Quality-by-Design (QbD) – A cornerstone of E6(R3), QbD encourages sponsors and investigators to proactively identify critical-to-quality factors—elements that directly impact participant safety and data reliability. Training must address this new focus .
Proportionality – E6(R3) introduces proportionality as a formal GCP principle. Trial procedures, oversight, and documentation should be scaled according to the risk, complexity, and context of the study .
Data Governance and Technology – E6(R3) expands guidance on the use of computerized systems, electronic records, and digital tools. Training must address data integrity, security, and system validation .
Fitness-for-Purpose – This concept defines quality as the ability of data and processes to serve their intended purpose. Training must help staff understand what is critical to quality .
Who Needs GCP Training Under ICH E6(R3)?
GCP training is required for all personnel involved in clinical trial activities, but the scope of training depends on their role. Not all staff need the same level of training; it depends on their role in the trial .
Principal Investigators – Must be thoroughly familiar with the guideline and all trial-related responsibilities. Regulatory agencies expect principal investigators to be familiarized with/trained in E6 R3 .
Sub-Investigators – Must be trained in the trial activities they perform, such as obtaining informed consent, registering and reporting adverse reactions .
Clinical Research Associates (Monitors) – Need training to understand their monitoring responsibilities under the new guideline.
Data Managers and Biostatisticians – Need training to understand data governance, integrity, and the use of digital tools .
Laboratory Technicians – A laboratory technician who routinely takes blood samples needs very little training, while a new trial-specific task would require additional training .
Retraining Considerations Under ICH E6(R3)
The question of retraining is critical with the adoption of ICH E6(R3). Regulatory agencies expect that for the major part of clinical trial staff, they will need some degree of retraining, due to the substantial amount of changes in the guideline .
Case-by-Case Assessment – The need for retraining depends on the role and tasks of the individual. If a person performs tasks in areas where the guideline has not changed, retraining is not required .
Principal Investigators – Regulatory agencies expect principal investigators to be familiarized with/trained in E6 R3, as they are one of the two legally responsible parties of a trial .
Delegated Staff – For persons or parties to whom the investigator has delegated trial-related activities, the need for retraining will depend on their tasks. If a person performs tasks in areas where the guideline has not changed, retraining is not required .
Frequency and Method – The appropriate amount, frequency, and methods of training are case-specific. Responsible parties must ensure that training and qualifications are sufficient for the tasks .
Regulatory Expectations for GCP Training
Regulatory agencies have clear expectations for GCP training under ICH E6(R3). These expectations help organizations understand what is required for compliance.
Documentation – Training must be documented and records must be maintained. This is essential for regulatory inspections.
Evidence of Qualifications – Investigators must provide evidence of their qualifications, including training records .
Sponsor Oversight – Sponsors must ensure that service providers’ staff training is sufficient. This requires documented assessment of training records .
Retraining Documentation – When retraining is provided, it must be documented and records must be maintained.
Global Recognition – GCP training that meets ICH E6(R3) requirements is recognized globally, enabling mutual recognition among sponsors .
Detailed Course Breakdown
Course 1: Good Clinical Practices (ICH Focused)
This comprehensive training program provides an in-depth exploration of the ICH E6(R3) Good Clinical Practice guideline, the globally recognized standard for the ethical and scientific quality of clinical trial design, conduct, and reporting. Finalized in January 2025, this latest revision represents a significant modernization of GCP principles, emphasizing a risk-based, proportionate approach to trial management and the integration of digital technologies.
Scope: The curriculum is structured to guide participants through the entire guideline, covering the 11 fundamental principles, the expanded roles and responsibilities of sponsors and investigators, rigorous data governance frameworks, and the critical requirements for essential records. Participants will gain a thorough understanding of how to apply the new principles-based framework to ensure participant protection, data integrity, and regulatory compliance across diverse trial designs, from traditional site-based studies to decentralized and hybrid models.
Description of Modules: The curriculum covers:
- ICH E6(R3) overview and its significance in global clinical research
- 11 Fundamental Principles of GCP and their application
- Quality-by-Design and proportionality concepts
- Sponsor responsibilities including oversight and quality management
- Investigator responsibilities including delegation and supervision
- Informed consent requirements and documentation
- Data governance and integrity frameworks
- Essential records and Trial Master File requirements
- Safety reporting and pharmacovigilance obligations
- Risk-based approaches to trial management
- Digital technologies and decentralized trial elements
Target Audience:
- Clinical Investigators and Sub-Investigators
- Sponsor Personnel (Medical, Regulatory, Clinical Operations)
- Clinical Research Associates (Monitors)
- IRB/IEC Members and Coordinators
- Data Management and Biostatistics Professionals
- Quality Assurance and Compliance Staff
- Clinical Trial Coordinators and Site Staff
- Pharmacovigilance and Safety Specialists
- Regulatory Affairs Professionals
- Clinical Research Organization (CRO) Personnel
Pricing: $149.00 with group discounts available.
FAQ:
- What is the difference between ICH E6(R2) and ICH E6(R3)? ICH E6(R3) introduces quality-by-design, proportionality, and a risk-based approach, while integrating digital technologies and decentralized trial models .
- What are the 11 fundamental principles of GCP? The 11 fundamental principles cover the ethical and scientific foundation of clinical trials, including participant safety, data integrity, and quality management .
- What is quality-by-design in clinical trials? Quality-by-design encourages sponsors and investigators to proactively identify critical-to-quality factors that directly impact participant safety and data reliability .
- What is the significance of Annex 1 in ICH E6(R3)? Annex 1 describes responsibilities and provides the basis for the appropriate interpretation and application of the principles .
- Is ICH E6(R3) training mandatory for clinical trial personnel? Yes, ICH E6(R3) is the global standard for GCP, and training on this guideline is mandatory for all personnel involved in clinical research .
Enroll Now: https://www.gxptrainings.com/courses/ich-e6r3-good-clinical-practices-gcp/
Course 2: Good Clinical Practices (Health Canada)
This comprehensive training program provides clinical research professionals with the knowledge and practical skills required to conduct clinical trials in compliance with Health Canada Food and Drug Regulations (Part C, Division 5) and the ICH E6(R3) Good Clinical Practice (GCP) guideline.
Scope: The curriculum is aligned with Health Canada’s adoption of ICH E6(R3) effective April 1, 2026. It covers Health Canada regulatory requirements, sponsor and Qualified Investigator responsibilities, clinical trial application processes, informed consent, safety reporting, data governance, quality management, and inspection readiness.
Description of Modules: The curriculum covers:
- Health Canada regulatory requirements for clinical trials (Part C, Division 5)
- ICH E6(R3) Good Clinical Practice principles and Annex 1
- Sponsor, Qualified Investigator, and REB responsibilities
- Clinical trial application (CTA) and amendment processes
- Informed consent requirements and participant protection
- Safety reporting obligations (AEs, SAEs, SUSARs)
- Data governance and record keeping requirements
- Quality management and risk-based monitoring
- Investigational product management and GMP compliance
- Clinical trial inspections and enforcement
Target Audience:
- Sponsors (commercial and non-commercial/academic)
- Qualified Investigators and Principal Investigators
- Research Ethics Board (REB) members and administrators
- Clinical Research Coordinators and study site personnel
- Contract Research Organizations (CROs) and Service Providers
- Clinical monitors and auditors
- Data managers and biostatisticians
- Regulatory affairs professionals
- Quality assurance professionals
- Pharmacovigilance professionals
Pricing: $249.00 with group discounts available.
FAQ:
- What is the deadline for updating GCP training to ICH E6(R3)? Health Canada implemented ICH E6(R3) on April 1, 2026. All clinical trial personnel should complete updated training .
- What is the role of the Qualified Investigator under Health Canada? The Qualified Investigator must be qualified by education, training, and experience, and must supervise the conduct of the clinical trial .
- What is the Clinical Trial Application (CTA) process in Canada? Sponsors must submit a CTA to Health Canada for authorization before initiating a clinical trial.
- What are the requirements for informed consent under Health Canada? Informed consent must be obtained from all participants before trial participation, with documentation in accordance with Part C, Division 5 requirements.
- What is ALCOA+ and why is it important? ALCOA+ is a set of principles for ensuring data integrity in clinical research.
Enroll Now: https://www.gxptrainings.com/courses/health-canada-good-clinical-practice-training/
Course 3: GCP Global Auditor Certification
This training program defines the complete knowledge and performance requirements for personnel involved in clinical research to become certified global auditors for Good Clinical Practice (GCP).
Scope: The program integrates GCP requirements from ICH E6(R3), Health Canada Part C, Division 5, and FDA regulations (21 CFR Parts 50, 56, 312, 314.50, and 314.80) with auditing practices based on ISO 19011:2026 for internal, second-party (vendor/CRO/site audits), and global regulatory compliance auditing.
Description of Modules: The curriculum covers:
- Regulatory Frameworks including ICH E6(R3), Health Canada Division 5, and FDA 21 CFR Parts 50, 56, 312, 314
- Auditing Practices based on ISO 19011:2026 including seven auditing principles
- Audit programme management including objectives, risks, resources, procedures, implementation, monitoring, review, and improvement
- Conducting an audit from initiation, preparation, execution, reporting, to follow-up
- Remote auditing methods including virtual audits, technology considerations, security, and contingency planning
- Competence and evaluation of auditors including personal behaviour, knowledge and skills, evaluation methods, and maintaining competence
Target Audience:
- Quality Assurance Personnel
- Clinical Research Associates (Monitors)
- Study Directors and Clinical Trial Managers
- Clinical Investigators and Site Staff
- Sponsor Personnel
- CRO Personnel
- IRB/IEC Members and Coordinators
- Data Management and Biostatistics Professionals
- Pharmacovigilance and Safety Specialists
- Regulatory Affairs Professionals
- Audit Program Managers
Pricing: $499.00 with group discounts available.
FAQ:
- What are the prerequisites for the GCP Global Auditor Certification? Completion of basic GCP awareness training and at least six months of experience in clinical research.
- What is ISO 19011:2026? ISO 19011:2026 provides guidelines for auditing management systems, covering audit principles, programme management, conduct, remote methods, and competence evaluation.
- What are the seven principles of auditing? The seven principles are integrity, fair presentation, due professional care, confidentiality, independence, evidence-based approach, and risk-based approach.
- What regulatory frameworks are covered in this program? The program covers ICH E6(R3), Health Canada Part C Division 5, and FDA 21 CFR Parts 50, 56, 312, 314.50, and 314.80.
- Can I conduct regulatory inspections with this certification? No, the program is designed for global auditing across internal, second-party, and regulatory readiness contexts.
Enroll Now: https://www.gxptrainings.com/courses/gcp-global-auditor-certification-program/
Course 4: HIPAA Clinical Data Privacy, Security & Compliance
This training program provides organizations and individuals with a comprehensive understanding of the legal, regulatory, and operational requirements for protecting health information in clinical research and healthcare delivery settings.
Scope: The program covers the full spectrum of privacy, security, and compliance obligations under U.S. federal law and international good practice standards. It includes protection of Protected Health Information (PHI) and Electronic Protected Health Information (ePHI), HIPAA Privacy, Security, and Breach Notification Rules, Good Clinical Practice (GCP) under ICH E6(R3), and security controls for information systems.
Description of Modules: The curriculum covers:
- HIPAA Overview and regulatory landscape
- HIPAA Privacy Rule requirements and PHI protections
- HIPAA Security Rule requirements and ePHI safeguards
- HIPAA Breach Notification Rule requirements
- GCP and clinical data integrity requirements
- Security controls for information systems and cloud environments
- Regulatory compliance frameworks including FDA, NIST, and ISO
- Incident management and breach response
- Risk assessment methodologies
- Roles and responsibilities of Sponsors, CROs, Investigators, and technology vendors
Target Audience:
- Covered Entities under HIPAA
- Business Associates and their subcontractors
- Clinical Research Professionals, including Sponsors, CROs, Principal Investigators, and IRBs
- Security and Compliance Professionals
Pricing: $249.00 with group discounts available.
FAQ:
- What is the difference between PHI and ePHI? PHI (Protected Health Information) is health information that identifies an individual, while ePHI is PHI that is created, stored, or transmitted electronically.
- What is the HIPAA Breach Notification Rule? It requires covered entities and business associates to notify affected individuals, the HHS, and in some cases the media, following a breach of unsecured PHI.
- How does HIPAA relate to GCP? HIPAA protects participant privacy in clinical research, while GCP ensures the ethical and scientific quality of trials.
- What is the role of a Business Associate under HIPAA? A Business Associate is a person or entity that performs certain functions or activities involving PHI on behalf of a covered entity.
- How often should HIPAA training be renewed? It is recommended to complete HIPAA training annually to stay current with regulatory updates and enforcement trends.
Enroll Now: https://www.gxptrainings.com/courses/hipaa-clinical-data-privacy-security-compliance-training/
Course 5: Validating AI in GxP
This comprehensive training program provides a deep and practical understanding of how to validate, govern, and maintain AI systems in GxP-regulated environments. It integrates the latest regulatory frameworks, including EU GMP Annex 11, the new Draft Annex 22, FDA’s Computer Software Assurance Guidance, 21 CFR Part 11, and the ISPE GAMP Guide: Artificial Intelligence.
Scope: The program addresses the critical question: “How do you validate something that can learn?” It covers AI system classification and risk tiering, data governance, performance acceptance criteria, test data management, ongoing monitoring, drift detection, and retraining governance.
Description of Modules: The curriculum covers:
- AI concepts, regulatory spine, and why AI validation breaks traditional CSV
- Classification and risk tiering, AI governance operating model, and AI validation master plan
- Data governance for AI, performance acceptance criteria, test data and the three independences, and IQ/OQ/PQ redefined for AI
- Ongoing monitoring and drift response, explainability and confidence, change control and retraining, and AI risk management
- Inspection readiness, generative AI in non-critical GxP use, LLMs in regulated environments, and building the AI programme
- AI and data integrity (ALCOA+), cybersecurity for AI systems, AI in combination products and SaMD, vendor management, and future trends
Target Audience:
- Validation Engineers and CSV Specialists
- Quality Assurance Professionals
- Data Scientists and AI/ML Engineers
- Regulatory Affairs Professionals
- IT and Cybersecurity Professionals
- Senior Management and AI Program Leaders
- Auditors and Inspectors
Pricing: $399.00 with group discounts available.
FAQ:
- Why does traditional CSV break when applied to AI? AI systems are adaptive and can learn over time, making static validation insufficient.
- What is the GAMP Guide: Artificial Intelligence? The ISPE GAMP Guide: Artificial Intelligence bridges established GAMP concepts with the unique characteristics of AI systems.
- What is Draft Annex 22? Draft Annex 22 is a new EU GMP Annex that provides a dedicated regulatory framework for AI models in the GMP environment.
- How do you validate AI systems? AI validation requires data governance, model drift monitoring, bias assessment, and explainability.
- What is the difference between AI validation and traditional software validation? AI validation requires ongoing monitoring and retraining governance due to the adaptive nature of AI systems.
Enroll Now: https://www.gxptrainings.com/courses/validating-ai-in-gxp-a-comprehensive-training/
Course 6: ISO 19011:2026 – Auditing Management Systems
This comprehensive training program is designed to provide individuals with a thorough understanding of ISO 19011:2026, “Guidelines for Auditing Management Systems.” This international standard provides guidance on auditing management systems, including the principles of auditing, managing an audit programme, and conducting management system audits, as well as guidance on the evaluation of competence of individuals involved in the audit process.
Scope: The program is applicable to all organizations that need to plan and conduct audits of management systems or manage an audit programme. The application of this document to other types of audits is possible, provided that special consideration is given to the specific competence needed and the objectives to be achieved.
Description of Modules: The curriculum covers:
- Auditing principles including integrity, fair presentation, due professional care, confidentiality, independence, evidence-based approach, and risk-based approach
- Audit programme management including objectives, risks, opportunities, resources, procedures, implementation, monitoring, review, and improvement
- Conducting an audit from initiation, preparation, execution, reporting, to follow-up
- Remote and hybrid auditing methods including virtual audits, technology considerations, security, and contingency planning
- Competence and evaluation of auditors including personal behaviour, knowledge and skills, evaluation methods, and maintaining competence
Target Audience:
- Quality Assurance Personnel
- Internal and External Auditors
- Audit Program Managers
- Compliance Professionals
- Regulatory Affairs Professionals
- Consultants and Service Providers
Pricing: $199.00 with group discounts available.
FAQ:
- What is ISO 19011:2026? ISO 19011:2026 provides guidelines for auditing management systems, covering audit principles, programme management, conduct, remote methods, and competence evaluation.
- What are the seven principles of auditing? The seven principles are integrity, fair presentation, due professional care, confidentiality, independence, evidence-based approach, and risk-based approach.
- What is remote auditing? Remote auditing uses virtual methods and technology to conduct audits, particularly useful for global clinical trials.
- How does ISO 19011 support GCP auditing? ISO 19011 provides the methodological framework for GCP auditing, ensuring audits are conducted professionally and consistently.
- What is the importance of auditor competence? Auditors must demonstrate personal behaviour, knowledge, skills, and maintain competence through ongoing evaluation.
Enroll Now: https://www.gxptrainings.com/courses/iso-190112026-auditing-management-systems/
Course 7: ANDA Regulatory Affairs Certification
This comprehensive training program is designed to provide pharmaceutical professionals with an in-depth understanding of the regulatory requirements, scientific principles, and practical considerations for submitting Abbreviated New Drug Applications (ANDAs) to the FDA.
Scope: The program covers the complete ANDA submission process, including bioequivalence studies, product development, and regulatory strategy. It is designed for professionals involved in generic drug development and regulatory affairs.
Description of Modules: The curriculum covers:
- ANDA Regulatory Framework and FDA requirements
- Bioequivalence Studies and their importance
- Product Development and formulation considerations
- Submission Requirements and documentation
- FDA Review Process and interactions
- Post-Approval Changes and lifecycle management
- Patent Certification and exclusivity provisions
- Quality by Design and risk management
Target Audience:
- Regulatory Affairs Professionals
- Pharmaceutical Development and Formulation Scientists
- Quality Assurance/Quality Control Professionals
- Clinical and Nonclinical Development Professionals
- CMC Specialists and Manufacturing Personnel
- Project Management Professionals
- CRO and CMO Personnel
- Legal and Intellectual Property Professionals
Pricing: $499.00 with group discounts available.
FAQ:
- What is an ANDA? An Abbreviated New Drug Application (ANDA) is a submission to the FDA for approval of a generic drug product.
- What is a bioequivalence study? A bioequivalence study demonstrates that the generic product delivers the same amount of active ingredient into the bloodstream as the reference product.
- What is the difference between an NDA and an ANDA? An NDA is submitted for new drugs, while an ANDA is submitted for generic drugs.
- What is the eCTD format? eCTD (Electronic Common Technical Document) is the standard format for regulatory submissions.
- What are the key elements of an ANDA submission? An ANDA submission includes bioequivalence data, product information, labeling, and manufacturing information.
Enroll Now: https://www.gxptrainings.com/courses/anda-regulatory-affairs-certification/
Course 8: Certified Regulatory Affairs Professional (CRAP)
This comprehensive certification program provides regulatory professionals with end-to-end knowledge of the global pharmaceutical regulatory landscape. The program covers the complete drug development lifecycle from discovery through post-approval lifecycle management, with specific focus on the regulatory requirements of the United States (FDA), European Union (EMA), and Japan (PMDA), as well as harmonization initiatives under ICH.
Scope: The program is structured to provide both foundational regulatory knowledge and advanced strategic capabilities across all major application types, including Investigational New Drug (IND) applications, New Drug Applications (NDA), Abbreviated New Drug Applications (ANDA), Biologics License Applications (BLA), Orphan Drug Designation, and Special Programs.
Description of Modules: The curriculum covers:
- Global Regulatory Framework overview
- Investigational New Drug (IND) applications
- New Drug Applications (NDA) for innovative pharmaceuticals
- Abbreviated New Drug Applications (ANDA) for generics
- Biologics License Applications (BLA) for biological products
- Orphan Drug Designation for rare disease treatments
- Special Programs including Accelerated Approval and Breakthrough Therapy
- Post-approval lifecycle management
- Regulatory agency interactions and meeting management
- Global regulatory strategy development
Target Audience:
- Regulatory Affairs Professionals
- Pharmaceutical Development and Formulation Scientists
- Quality Assurance/Quality Control Professionals
- Clinical and Nonclinical Development Professionals
- CMC Specialists and Manufacturing Personnel
- Project Management Professionals
- CRO and CMO Personnel
- Legal and Intellectual Property Professionals
Pricing: $799.00 with group discounts available.
FAQ:
- What is the difference between an IND and an NDA? An IND (Investigational New Drug) application is submitted to authorize clinical trials, while an NDA (New Drug Application) is submitted to obtain marketing approval for a new drug.
- What is the eCTD format and why is it important? eCTD (Electronic Common Technical Document) is the standard format for regulatory submissions, enabling efficient review and global harmonization.
- What is the purpose of an Orphan Drug Designation? Orphan Drug Designation is granted to drugs intended for the treatment of rare diseases, providing incentives such as market exclusivity and tax credits.
- What is the role of ICH in global drug development? ICH develops guidelines that harmonize regulatory requirements across regions, facilitating efficient global drug development.
- What are the key elements of a Biologics License Application (BLA)? A BLA includes manufacturing information, nonclinical studies, clinical data, and labeling for biological products.
Enroll Now: https://www.gxptrainings.com/courses/certified-regulatory-affairs-professional/
Get Your Team Offer
For organizations looking to enroll multiple participants, we offer specialized team packages and volume discounts. Please reach out to our partnership team to discuss your specific needs and scores.
Contact Us: https://www.gxptrainings.com/contact-us/
Author
